Synopsis
Synopsis
0
USDMF
0
CEP/COS
0
JDMF
0
EU WC
0
KDMF
0
NDC API
0
VMF
0
FDF
0
Europe
0
Canada
0
Australia
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
EDQM
0
USP
0
JP
0
Others
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
US Medicaid
NA
Annual Reports
NA
Finished Drug Prices
NA
1. (6r)-6-(2-(ethyl((4-(2-(ethylamino)ethyl)phenyl)methyl)amino)-4-methoxyphenyl)-5,6,7,8-tetrahydronaphthalen-2-ol
1. 722533-56-4
2. Rad1901
3. Elacestrant [inn]
4. Elacestrant [usan]
5. Rad-1901
6. Er-306323
7. Fm6a2627a8
8. (6r)-6-[2-[ethyl-[[4-[2-(ethylamino)ethyl]phenyl]methyl]amino]-4-methoxyphenyl]-5,6,7,8-tetrahydronaphthalen-2-ol
9. (6r)-6-{2-[ethyl({4-[2-(ethylamino)ethyl]phenyl}methyl)amino]-4-methoxyphenyl}-5,6,7,8-tetrahydronaphthalen-2-ol
10. (2r)-2-(2-(ethyl-((4-(2-(ethylamino)ethyl)phenyl)methyl)amino)-4-methoxy-phenyl)tetralin-6-ol
11. (6r)-6-(2-(ethyl((4-(2- (ethylamino)ethyl)phenyl)methyl)amino)-4-methoxyphenyl)- 5,6,7,8-tetrahydronaphthalen-2-ol
12. 2-naphthalenol, 6-(2-(ethyl((4-(2-(ethylamino)ethyl)phenyl)methyl)amino)-4-methoxyphenyl)-5,6,7,8-tetrahydro-, (6r)-
13. Elacestrant (usan/inn)
14. Elacestrant [usan:inn]
15. Elacestrant [who-dd]
16. Schembl229431
17. Unii-fm6a2627a8
18. Chembl4297509
19. Bdbm349630
20. Dtxsid901045846
21. Glxc-26208
22. Ex-a5070
23. Us10208011, Compound Rad-
24. Mfcd30532693
25. Who 10247
26. Cs-6306
27. Db06374
28. Hy-19822
29. D11671
30. Q27278069
31. (r)-6-(2-(ethyl(4-(2-(ethylamino)ethyl)benzyl)amino)-4-methoxyphenyl)-5,6,7,8-tetrahydronaphthalen-2-ol
32. I0v
Molecular Weight | 458.6 g/mol |
---|---|
Molecular Formula | C30H38N2O2 |
XLogP3 | 6.3 |
Hydrogen Bond Donor Count | 2 |
Hydrogen Bond Acceptor Count | 4 |
Rotatable Bond Count | 10 |
Exact Mass | 458.293328459 g/mol |
Monoisotopic Mass | 458.293328459 g/mol |
Topological Polar Surface Area | 44.7 Ų |
Heavy Atom Count | 34 |
Formal Charge | 0 |
Complexity | 578 |
Isotope Atom Count | 0 |
Defined Atom Stereocenter Count | 1 |
Undefined Atom Stereocenter Count | 0 |
Defined Bond Stereocenter Count | 0 |
Undefined Bond Stereocenter Count | 0 |
Covalently Bonded Unit Count | 1 |
Investigated for use/treatment in menopause and female hormonal deficiencies/abnormalities.
RAD1901 is a novel selective estrogen receptor modulator(SERM). SERMs are small molecules that bind to and selectively modulate estrogen receptors. These molecules have the ability to stimulate or block estrogen's activity in different types of tissue, functioning as estrogen receptor agonists in some tissues and as estrogen receptor antagonists in others. RAD1901 has potential to reduce vasomotor symptoms, along with a simultaneous bone-protective effect, without stimulating breast or uterine tissues. RAD1901 is distinctive from other SERMs in its unique biological profile, combined with its significant ability to penetrate the blood-brain barrier, which enables RAD1901 to function as an estrogen agonist within the central nervous system and thereby relieve hot flashes.
Granules India Limited has high volume world-class facilities for APIs, PFIs, & FDFs, serving customers in over 80 countries.
Seqens is an integrated global leader in pharmaceutical solutions & specialty ingredients & provides custom-made solutions.
Granules India Limited has high volume world-class facilities for APIs, PFIs, & FDFs, serving customers in over 80 countries.
About the Company : Granules is a vertically integrated fast-growing Pharmaceutical company headquartered in Hyderabad with best-in-class facilities & a commitment to operational excellence, quality, ...
Seqens is an integrated global leader in pharmaceutical solutions & specialty ingredients & provides custom-made solutions.
About the Company : Since its inception in 2003, Seqens has grown to become a global leader in pharmaceutical solutions and specialty ingredients. Seqens supports its customers in developing, scaling ...
About the Company : Since its founding in 1962, MOEHS has produced Active Pharmaceutical Ingredients (APIs) for the international pharmaceutical industry. Thanks to a business history of more than 50 ...
About the Company : Established in May 2012, Shandong Loncom Pharmaceutical operates as a fully owned subsidiary of Shandong Bestcomm Pharmaceutical Co., Ltd. Situated in the Qihe Economic Development...
Details:
Rupitasertib is an oral inhibitor of S6K and AKT1/AKT3 designed to block the PI3K/AKT/mTOR pathway, being investigated with elacestrant in ER+/HER2- advanced breast cancer with ESR1 mutation.
Lead Product(s): Rupitasertib,Elacestrant
Therapeutic Area: Oncology Brand Name: Undisclosed
Study Phase: Phase IProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 22, 2024
Lead Product(s) : Rupitasertib,Elacestrant
Therapeutic Area : Oncology
Highest Development Status : Phase I
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Evexta Bio Reports Progress On Rupitasertib for Advanced Breast Cancer
Details : Rupitasertib is an oral inhibitor of S6K and AKT1/AKT3 designed to block the PI3K/AKT/mTOR pathway, being investigated with elacestrant in ER+/HER2- advanced breast cancer with ESR1 mutation.
Brand Name : Undisclosed
Molecule Type : Small molecule
Upfront Cash : Not Applicable
April 22, 2024
Details:
Under the agreement, SciClone will pursue the development and registration of Orserdu (elacestrant), a once-daily oral endocrine monotherapy, for the treatment of postmenopausal women or adult men, in China and commercialize Orserdu upon its regulatory approval in China.
Lead Product(s): Elacestrant
Therapeutic Area: Oncology Brand Name: Orserdu
Study Phase: ApprovedProduct Type: Small molecule
Sponsor: SciClone Pharmaceuticals
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement November 07, 2023
Lead Product(s) : Elacestrant
Therapeutic Area : Oncology
Highest Development Status : Approved
Partner/Sponsor/Collaborator : SciClone Pharmaceuticals
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Details : Under the agreement, SciClone will pursue the development and registration of Orserdu (elacestrant), a once-daily oral endocrine monotherapy, for the treatment of postmenopausal women or adult men, in China and commercialize Orserdu upon its regulatory a...
Brand Name : Orserdu
Molecule Type : Small molecule
Upfront Cash : Undisclosed
November 07, 2023
Details:
Orserdu (elacestrant), an estrogen receptor antagonist that binds to estrogen receptor-alpha (ERα), is indicated for the treatment of postmenopausal women, and men, with ER‑positive, HER2-negative, locally advanced or metastatic breast cancer with an activating ESR1 mutation.
Lead Product(s): Elacestrant
Therapeutic Area: Oncology Brand Name: Orserdu
Study Phase: ApprovedProduct Type: Small molecule
Sponsor: European Organisation for Research and Treatment of Cancer
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 19, 2023
Lead Product(s) : Elacestrant
Therapeutic Area : Oncology
Highest Development Status : Approved
Partner/Sponsor/Collaborator : European Organisation for Research and Treatment of Cancer
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : Orserdu (elacestrant), an estrogen receptor antagonist that binds to estrogen receptor-alpha (ERα), is indicated for the treatment of postmenopausal women, and men, with ER‑positive, HER2-negative, locally advanced or metastatic breast cancer with an ...
Brand Name : Orserdu
Molecule Type : Small molecule
Upfront Cash : Not Applicable
October 19, 2023
Details:
Orserdu (elacestrant), an estrogen receptor antagonist that binds to estrogen receptor-alpha (ERα), is indicated for the treatment of postmenopausal women, and men, with estrogen receptor (ER)‑positive, HER2-negative, locally advanced or metastatic breast cancer.
Lead Product(s): Elacestrant
Therapeutic Area: Oncology Brand Name: Orserdu
Study Phase: ApprovedProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 20, 2023
Lead Product(s) : Elacestrant
Therapeutic Area : Oncology
Highest Development Status : Approved
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
European Commission Approves Menarini Group’s ORSERDU® (Elacestrant) for the Treatment of Patie...
Details : Orserdu (elacestrant), an estrogen receptor antagonist that binds to estrogen receptor-alpha (ERα), is indicated for the treatment of postmenopausal women, and men, with estrogen receptor (ER)‑positive, HER2-negative, locally advanced or metastatic br...
Brand Name : Orserdu
Molecule Type : Small molecule
Upfront Cash : Not Applicable
September 20, 2023
Details:
Under the agreement, DRI Healthcare gains a portion of Radius’s royalty and commercial milestone stream in Orserdu (elacestrant), a selective estrogen receptor degrader and the first and only treatment approved for ER+/HER2-, ESR1- mutated advanced or metastatic breast cancer.
Lead Product(s): Elacestrant
Therapeutic Area: Oncology Brand Name: Orserdu
Study Phase: ApprovedProduct Type: Small molecule
Sponsor: DRI Healthcare
Deal Size: $140.0 million Upfront Cash: $130.0 million
Deal Type: Agreement August 14, 2023
Lead Product(s) : Elacestrant
Therapeutic Area : Oncology
Highest Development Status : Approved
Partner/Sponsor/Collaborator : DRI Healthcare
Deal Size : $140.0 million
Deal Type : Agreement
Details : Under the agreement, DRI Healthcare gains a portion of Radius’s royalty and commercial milestone stream in Orserdu (elacestrant), a selective estrogen receptor degrader and the first and only treatment approved for ER+/HER2-, ESR1- mutated advanced or ...
Brand Name : Orserdu
Molecule Type : Small molecule
Upfront Cash : $130.0 million
August 14, 2023
Details:
Orserdu (elacestrant), an estrogen receptor antagonist that binds to estrogen receptor-alpha (ERα), is indicated for the treatment of postmenopausal women, and men, with ER‑positive, HER2-negative, locally advanced or metastatic breast cancer with an activating ESR1 mutation.
Lead Product(s): Elacestrant
Therapeutic Area: Oncology Brand Name: Orserdu
Study Phase: ApprovedProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 21, 2023
Lead Product(s) : Elacestrant
Therapeutic Area : Oncology
Highest Development Status : Approved
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Menarini Group Receives Positive CHMP Opinion Recommending EC Approval of ORSERDU® (Elacestrant) ...
Details : Orserdu (elacestrant), an estrogen receptor antagonist that binds to estrogen receptor-alpha (ERα), is indicated for the treatment of postmenopausal women, and men, with ER‑positive, HER2-negative, locally advanced or metastatic breast cancer with an ...
Brand Name : Orserdu
Molecule Type : Small molecule
Upfront Cash : Not Applicable
July 21, 2023
Details:
Under the agreement, Eisai transfers all future economic rights for elacestrant, a selective estrogen receptor degrader, approved for the treatment for breast cancer in the United States, to DRI Healthcare Trust.
Lead Product(s): Elacestrant
Therapeutic Area: Oncology Brand Name: Elacestrant-Generic
Study Phase: ApprovedProduct Type: Small molecule
Sponsor: DRI Healthcare
Deal Size: Undisclosed Upfront Cash: $85.0 million
Deal Type: Agreement June 29, 2023
Lead Product(s) : Elacestrant
Therapeutic Area : Oncology
Highest Development Status : Approved
Partner/Sponsor/Collaborator : DRI Healthcare
Deal Size : Undisclosed
Deal Type : Agreement
Details : Under the agreement, Eisai transfers all future economic rights for elacestrant, a selective estrogen receptor degrader, approved for the treatment for breast cancer in the United States, to DRI Healthcare Trust.
Brand Name : Elacestrant-Generic
Molecule Type : Small molecule
Upfront Cash : $85.0 million
June 29, 2023
Details:
Orserdu (elacestrant) is an estrogen receptor antagonist that binds to estrogen receptor-alpha (ERα). It inhibits 17β-estradiol mediated cell proliferation at concentrations inducing degradation of ERα protein mediated through proteasomal pathway.
Lead Product(s): Elacestrant
Therapeutic Area: Oncology Brand Name: Orserdu
Study Phase: ApprovedProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 02, 2023
Lead Product(s) : Elacestrant
Therapeutic Area : Oncology
Highest Development Status : Approved
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
ORSERDU™ Now Available from Onco360 for the Treatment of Postmenopausal Women or Adult Men, with...
Details : Orserdu (elacestrant) is an estrogen receptor antagonist that binds to estrogen receptor-alpha (ERα). It inhibits 17β-estradiol mediated cell proliferation at concentrations inducing degradation of ERα protein mediated through proteasomal pathway.
Brand Name : Orserdu
Molecule Type : Small molecule
Upfront Cash : Not Applicable
February 02, 2023
Details:
Orserdu (elacestrant) is an estrogen receptor antagonist that binds to estrogen receptor-alpha (ERα). It inhibits 17β-estradiol mediated cell proliferation at concentrations inducing degradation of ERα protein mediated through proteasomal pathway.
Lead Product(s): Elacestrant
Therapeutic Area: Oncology Brand Name: Orserdu
Study Phase: ApprovedProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 30, 2023
Lead Product(s) : Elacestrant
Therapeutic Area : Oncology
Highest Development Status : Approved
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Stemline Therapeutics, a Subsidiary of Menarini Group, Receives U.S. FDA Approval for Orserdu™ (...
Details : Orserdu (elacestrant) is an estrogen receptor antagonist that binds to estrogen receptor-alpha (ERα). It inhibits 17β-estradiol mediated cell proliferation at concentrations inducing degradation of ERα protein mediated through proteasomal pathway.
Brand Name : Orserdu
Molecule Type : Small molecule
Upfront Cash : Not Applicable
January 30, 2023
Details:
RAD1901 (elacestrant) is an investigational selective estrogen receptor degrader (SERD). Preclinical studies indicate that the compound has the potential for use as a single agent or in combination with other therapies for the treatment of breast cancer.
Lead Product(s): Elacestrant
Therapeutic Area: Oncology Brand Name: RAD1901
Study Phase: Phase IIIProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 30, 2022
Lead Product(s) : Elacestrant
Therapeutic Area : Oncology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : RAD1901 (elacestrant) is an investigational selective estrogen receptor degrader (SERD). Preclinical studies indicate that the compound has the potential for use as a single agent or in combination with other therapies for the treatment of breast cancer.
Brand Name : RAD1901
Molecule Type : Small molecule
Upfront Cash : Not Applicable
November 30, 2022
6-(benzyloxy)-3,4-dihydronaphthalen-1(2H)-one
CAS Number : 32263-70-0
End Use API : Elacestrant
About The Company : LinkChem is a leading China headquartered CMO | CRO provider within the pharmaceutical industry. Our core focus includes: custom synthesis, process development,...
Market Place
Reply
01 Aug 2023
Patents & EXCLUSIVITIES
Patent Expiration Date : 2034-10-10
US Patent Number : 10420734
Drug Substance Claim :
Drug Product Claim :
Application Number : 217639
Patent Use Code : U-3524
Delist Requested :
Patent Use Description :
Patent Expiration Date : 2034-10-10
Patent Expiration Date : 2038-01-05
US Patent Number : 10745343
Drug Substance Claim :
Drug Product Claim :
Application Number : 217639
Patent Use Code : U-3523
Delist Requested :
Patent Use Description :
Patent Expiration Date : 2038-01-05
Patent Expiration Date : 2034-10-10
US Patent Number : 11779552
Drug Substance Claim :
Drug Product Claim :
Application Number : 217639
Patent Use Code : U-3524
Delist Requested :
Patent Use Description :
Patent Expiration Date : 2034-10-10
Patent Expiration Date : 2026-08-18
US Patent Number : 7612114
Drug Substance Claim : Y
Drug Product Claim : Y
Application Number : 217639
Patent Use Code : U-3523
Delist Requested :
Patent Use Description :
Patent Expiration Date : 2026-08-18
Patent Expiration Date : 2038-01-05
US Patent Number : 10385008
Drug Substance Claim : Y
Drug Product Claim : Y
Application Number : 217639
Patent Use Code :
Delist Requested :
Patent Use Description :
Patent Expiration Date : 2038-01-05
Patent Expiration Date : 2026-08-18
US Patent Number : 7612114
Drug Substance Claim : Y
Drug Product Claim : Y
Application Number : 217639
Patent Use Code : U-3523
Delist Requested :
Patent Use Description :
Patent Expiration Date : 2026-08-18
Patent Expiration Date : 2038-01-05
US Patent Number : 10385008
Drug Substance Claim : Y
Drug Product Claim : Y
Application Number : 217639
Patent Use Code :
Delist Requested :
Patent Use Description :
Patent Expiration Date : 2038-01-05
Patent Expiration Date : 2034-10-10
US Patent Number : 10420734
Drug Substance Claim :
Drug Product Claim :
Application Number : 217639
Patent Use Code : U-3524
Delist Requested :
Patent Use Description :
Patent Expiration Date : 2034-10-10
Patent Expiration Date : 2034-10-10
US Patent Number : 10071066
Drug Substance Claim :
Drug Product Claim :
Application Number : 217639
Patent Use Code : U-3524
Delist Requested :
Patent Use Description :
Patent Expiration Date : 2034-10-10
Patent Expiration Date : 2034-10-10
US Patent Number : 11779552
Drug Substance Claim :
Drug Product Claim :
Application Number : 217639
Patent Use Code : U-3524
Delist Requested :
Patent Use Description :
Patent Expiration Date : 2034-10-10
ABOUT THIS PAGE
LOOKING FOR A SUPPLIER?